Cellular Transfer of Cutaneous Sensitivity to Hemolytic Streptococci.
Abstract
Transfer Factor (TF) has emerged as one of the more potent immunologic reagents proven effective in the initiation, augmentation or reconstitution of delayed hypersensitivity (DTH) and cell-mediated immunity (CMI) in humans. TF is a small (<10,000 M.W.) non-antigenic, non-immunoglobulin moiety that is separated from the macromolecules of human blood leukocytes by dialysis, further purified by Sephadex fractionation and concentrated by lyophilization. Dialysable TF (TFD) and the partially purified Sephadex fractions possess the immunological activities of the viable leukocytes from which it is prepared, namely TF confers on the normal recipient for prolonged periods the DTH and CMI possessed by the immune donor. The established effectiveness of TFD is selectively augmenting cellular immunity has fostered its widespread application in the immunotherapy of a variety of congenital and acquired diseases characterized by deficient CMI. Operationally TFD administration results in the appearance of a new population of antigen-responsive lymphocytes in the recipient's circulation which in the presence of the related antigen express the activities of the natively immune cell. In addition to the antigen-specific responses, TFD administration results in a nonspecific augmentation of CMI responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 1977
- Accession Number
- ADA051694
Entities
People
- H. Sherwood Lawrence
Organizations
- NYU Langone Health